133 related articles for article (PubMed ID: 19910070)
1. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.
Nakamoto S; Imazeki F; Fukai K; Fujiwara K; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
J Hepatol; 2010 Jan; 52(1):72-8. PubMed ID: 19910070
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Seko Y; Akuta N; Suzuki F; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):13-21. PubMed ID: 22907167
[TBL] [Abstract][Full Text] [Related]
3. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.
Yuen MF; Tanaka Y; Fong DY; Fung J; Wong DK; Yuen JC; But DY; Chan AO; Wong BC; Mizokami M; Lai CL
J Hepatol; 2009 Jan; 50(1):80-8. PubMed ID: 18977053
[TBL] [Abstract][Full Text] [Related]
4. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
6. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
[TBL] [Abstract][Full Text] [Related]
7. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
[TBL] [Abstract][Full Text] [Related]
8. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
9. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
10. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
11. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.
Bruno S; Silini E; Crosignani A; Borzio F; Leandro G; Bono F; Asti M; Rossi S; Larghi A; Cerino A; Podda M; Mondelli MU
Hepatology; 1997 Mar; 25(3):754-8. PubMed ID: 9049231
[TBL] [Abstract][Full Text] [Related]
13. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.
Kobayashi M; Akuta N; Suzuki F; Hosaka T; Sezaki H; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Watahiki S; Mineta R; Iwasaki S; Miyakawa Y; Kumada H
J Med Virol; 2010 Jan; 82(1):41-8. PubMed ID: 19950230
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
17. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
18. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.
Yamauchi M; Nakahara M; Maezawa Y; Satoh S; Nishikawa F; Ohata M; Mizuhara Y; Hirakawa J; Nakajima H; Fujisawa K
Am J Gastroenterol; 1993 Jan; 88(1):39-43. PubMed ID: 7678368
[TBL] [Abstract][Full Text] [Related]
20. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]